Skip to main content

2020

2020-12-23
The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) today announces the outcome of the fully guaranteed rights issue of units with preferential rights for Moberg Pharma’s shareholders (the “Rights Issue”) which was resolved upon by the Board of Directors on November 6[th], 2020 and approved by an extraordinary general meeting on December 1[st], 2020. In total, 16,434,319 units were subscribed for with support of unit subscription rights, corresponding to approximately 71 percent of the Rights Issue. The remaining 6,741,257 units, corresponding to approximately 29 percent of the Rights Issue, have been allotted to persons who have subscribed for units without support of unit subscription rights, whereof 5,046,873 units, corresponding to approximately 22 percent of the Rights Issue, have been allotted to external subscription committers. The Rights Issue is thus fully subscribed for and no issue guarantees have been required to be used. Moberg Pharma will thereby receive approximately MSEK 150 before deduction for transaction costs.
2020-12-16
OncoZenge AB (publ) (“OncoZenge”), Moberg Pharma AB (publ)’s subsidiary, has at an Extraordinary Shareholders Meeting today resolved on expanding the board with Hilde Furberg ahead of the listing on Nasdaq First North Growth Market, which is planned to take place during the first quarter of 2021.
2020-12-11
OncoZenge AB (publ) (“OncoZenge”), Moberg Pharma AB (publ)’s subsidiary, has today resolved on a directed share issue in accordance with the press release from November 16[th], 2020 (the “Directed Issue”). The Directed Issue of MSEK 10 is the first step of the secured financing in OncoZenge of MSEK 70 in total. The share issue is carried out to secure OncoZenge’s initial working capital requirements ahead of the listing on Nasdaq First North Growth Market, which is planned to take place during the first quarter of 2021.
2020-12-03
Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) announces that the prospectus relating to the Company’s fully guaranteed rights issue of units consisting of ordinary shares and warrants (the “Rights Issue”) has been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company’s website www.mobergpharma.se/investerare/prospekt and will also be available at the Swedish Financial Supervisory Authority’s website www.fi.se.
2020-12-03
The correction refers to the second last sentence of the first paragraph under the heading “Terms for the Rights Issue”. The sentence should rightfully have the wording following below, which was included in the decision by the board of directors on the rights issue, as published on 10 November 2020. This means that the words “70 per cent of” by mistake were omitted in the press release from 27 November 2020.
2020-12-01
STOCKHOLM, December 1[st], 2020. Moberg Pharma AB (publ)’s (OMX: MOB) (“Moberg Pharma” or the “Company”) Extraordinary General Meeting took place today. The Extraordinary General Meeting resolved as set out below.
2020-11-30
STOCKHOLM, November 30[th], 2020 – Moberg Pharma AB (publ) (”Moberg Pharma” or the ”Company”) has obtained a positive decision confirming that the Swedish Tax Agency shares the Company’s assessment that the Company’s proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act, which means that the distribution will not be subject to taxation for the Company’s shareholders.
2020-11-30
STOCKHOLM, November 30[th] 2020. During November 2020, the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) (“Moberg Pharma” or the “Company”) has increased due to conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.
2020-11-27
STOCKHOLM, November 27[th], 2020 – On November 10[th], 2020, Moberg Pharma AB (publ) (”Moberg Pharma” or the ”Company”) published its interim report for the period July 2019 – September 2020. The Company today publishes an audited interim report for the same period. The audit has not resulted in any adjustments to the financial numbers published on November 10[th], 2020.
2020-11-27
On 6 November 2020, the board of directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) announced that the board of directors had resolved to, subject to the approval of the extraordinary general meeting to be held on 1 December 2020 (the “EGM”), carry out a fully guaranteed rights issue of ordinary shares and warrants (“Units”) with preferential rights for existing shareholders in the amount of approximately MSEK 150 before transaction costs (the “Rights Issue”). The board of directors of Moberg Pharma today announces the final terms of the Rights Issue. Existing shareholders in Moberg Pharma as of the record date, 3 December 2020, will receive seven (7) unit rights per one (1) existing share. Six (6) unit rights entitle to subscription of one (1) Unit in the Rights Issue. Each Unit consist of one (1) ordinary share and one (1) warrant issued without cost. The subscription price is SEK 6.47 per Unit.
2020-11-23
STOCKHOLM, November 23[rd], 2020 - On November 25[th], 2020, at 02:00 am (CET), investors, analysts and journalists are invited to participate in a digital company presentation. Moberg pharma recently announced its intention to distribute its subsidiary OncoZenge through a Lex ASEA distribution before listing the company on Nasdaq First North Growth Market, as well as securing financing both for OncoZenge and Moberg Pharma.
2020-11-16
 Moberg Pharma’s subsidiary OncoZenge has received binding undertakings  regarding a directed issue of shares of SEK 10 million and a fully secured rights issue of shares of approximately SEK 60 million. The investors, which include John Fällström, Linc AB and Moberg Pharma’s largest shareholder, Östersjöstiftelsen, are subscribing for shares in the directed issue and have committed to subscribe for their parts and guarantee the remainder of the rights issue in OncoZenge.
2020-11-10
Registration preparations in Europe, Financing for MOB-015 secured and spin-off of BUPI  
2020-11-06
The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or “the Company”) has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants (“Units”) with preferential rights for existing shareholders (the “Rights Issue”) of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the “Extraordinary General Meeting”). The proceeds will be used for registration activities and clinical work for MOB-015. When the Rights Issue is completed, the Company intends to terminate the current convertible note agreement. By a separate press release, the Company has today announced its intention to distribute the BUPI project to the shareholders of Moberg Pharma through a Lex Asea distribution with a subsequent listing on Nasdaq First North Growth Market during the Q1 of 2021.
2020-11-06
The Board of Directors of Moberg Pharma AB (OMX: MOB) today announces its intention to distribute the operations of BupiZenge[®] (BUPI) to the shareholders of Moberg Pharma by distributing 90 percent of the shares in a subsidiary (name to be changed to OncoZenge AB) through a so-called Lex ASEA distribution, and convenes an extraordinary general meeting to resolve accordingly. The business consists of developing the BUPI project under the brand name BupiZenge[®] for treatment of oral mucositis. Moberg Pharma estimates the capital requirement to take BupiZenge[®] through phase 3 at SEK 60 million. Moberg Pharma is therefore evaluating the opportunity to distribute OncoZenge according to Lex Asea and list its shares on Nasdaq First North Growth Market. Moberg Pharma has hired Erik Penser Bank to evaluate opportunities for financing OncoZenge as a separate company.
2020-11-06
The shareholders of Moberg Pharma AB (publ) (reg. no. 556697-7426) (the ”Company” or ”Moberg Pharma”) are hereby invited to the Extraordinary General Meeting on Tuesday, 1 December 2020. In order to reduce the spread of the virus causing COVID-19, the Board of Directors has decided that the Extraordinary General Meeting shall be held without physical presence of shareholders, proxies and/or external parties and that the shareholders shall have the opportunity to vote by mail prior to the Extraordinary General Meeting.
2020-11-05
STOCKHOLM, November 5[th], 2020 – In accordance with the resolution of the Annual General Meeting on October 30[th], 2019, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on October 30[th], 2019.
2020-11-03
STOCKHOLM, November 3[rd], 2020 - On November 10[th], 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - September 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
2020-10-14
STOCKHOLM, October 14[th], 2020, Moberg Pharma AB (OMX: MOB) announced today its decision to request pre-submission meetings with regulatory agencies, with the goal of submitting a registration application in the second half of 2021 in Europe.
2020-09-30
STOCKHOLM, September 30[th] 2020. During September 2020, the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) (“Moberg Pharma” or the “Company”) has increased due to conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.
2020-08-11

The Primary endpoint was met in the Phase 3 study

2020-08-04

STOCKHOLM, August 4th, 2020 - On August 11th, 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - June 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.

2020-07-30

STOCKHOLM, July 30th, 2020, Moberg Pharma AB (OMX: MOB) announces the appointment of Dr Cindy Wong as Chief Medical Officer of Moberg Pharma. Dr Wong will during the fall be joining the management team at Moberg Pharma coming from a previous position as Vice President and Head of Global Clinical Development at Metz Pharmaceuticals GmbH.

2020-06-30

STOCKHOLM, June 30th 2020. During June 2020, the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) (“Moberg Pharma” or the “Company”) has increased due to conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.

2020-06-25

STOCKHOLM, June 25th, 2020, Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) met the primary endpoint in the European Phase 3 study including 452 onychomycosis patients, showing non-inferiority versus topical ciclopirox. Mycological cure was achieved in 84 percent of patients, which is unprecedented for a topical treatment and even higher than reported for oral treatments. The pattern is consistent with the results from the North American Phase 3 study, with low complete cure rates despite the high mycological cure rates. Moberg Pharma will discuss next steps with partners and regulatory agencies.

2020-05-29

STOCKHOLM, May 29th, 2020, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 19,223,510. The 370,000 newly issued shares are held by the company to secure its commitments under incentive programmes.

2020-05-19

STOCKHOLM, May 19th, 2020, Moberg Pharma AB (OMX: MOB) announced that the board of directors exercises authorizations to issue and repurchase C-shares, and converts C-shares to common shares, to secure the company’s commitments under incentive programme.

2020-05-12

FINANCING AGREEMENT OF UP TO SEK 216 MILLION FOR FURTHER INVESTMENTS IN MOB-015

2020-05-05

STOCKHOLM, May 5th, 2020 - On May 12th, 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - March 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.

2020-04-28

STOCKHOLM, April 28th, 2020. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Extraordinary General Meeting took place today in the Company’s premises in Bromma. The Extraordinary General Meeting resolved as set out below.

2020-03-27
The shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company” or “Moberg Pharma”) are hereby convened to the Extraordinary General Meeting on Tuesday, 28 April 2020 at 4:30 p.m. (CET) in the Company’s premises in Bromma, address Gustavslundsvägen 42, 5 tr, 167 51 Bromma (Alviks torg), Sweden.
2020-03-23
STOCKHOLM, March 23[rd], 2020 - Moberg Pharma AB (publ) announces today that the company has entered into a convertible note agreement with Nice & Green S.A. (“N&G”), contingent on an authorization at an Extraordinary General Meeting. In December 2019, the company reported that the primary endpoint for MOB-015 was met in the North American phase 3 study. The evaluation of the study results showed that the rapid and high antifungal effect of MOB-015 is world leading, but that dosing may be optimized. Based on these data, MOB-015 has the potential to become the future market leader in onychomycosis. The agreement with N&G enables Moberg Pharma to pursue this potential and conduct an additional clinical study, depending on the outcome of the EU study expected at the end of Q2 2020.
2020-03-23
STOCKHOLM, March 23[rd], 2020 - Moberg Pharma AB (publ) announces that all patients in the European MOB-015 Phase 3 study have completed their last study visit. The data collection in the study were completed without any negative impact from COVID-19. The timeline remains unchanged with topline results expected by the end of the second quarter.  
2020-02-11
PRIMARY ENDPOINT REACHED IN THE PHASE 3 STUDY
2020-02-04
STOCKHOLM, February 4[th], 2020 - On February 11[th], 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July - December 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
2020-01-22
STOCKHOLM, January 22[nd], 2020. Moberg Pharma AB (OMX: MOB) has now completed the expert evaluation of the results from the North American Phase 3-study. The analysis conducted with key opinion leaders (KOLs) has confirmed the validity of the data presented in December 2019 and increased the understanding of the study outcomes. Key conclusions include: i) MOB-015 delivers a very high mycological cure rate that compares favorably to oral antifungal drugs with the added advantage of an earlier onset of action; ii) Confirmation that the proprietary vehicle technology increases the hydration and permeability of the nail plate enabling efficient terbinafine delivery, however  it also confounds the  assessment of clinical cure and complete cure and iii) A likely solution to the problem – a shorter dosing regimen with the potential to deliver superior complete cure rates.
2020-01-14
 Moberg Pharma AB (OMX: MOB) announces that the Swedish Tax Agency has published a notification on distribution of the acquisition cost of shares as a consequence of the redemption in 2019 of shares in Moberg Pharma AB for cash proceeds of SEK 46.50 per share.